To review the effects of statin use in patients at risk for or diagnosed with Clostridium difficile infection (CDI) on CDI incidence, treatment success, and mortality.
Methods
A literature search was performed through January 2019 using the following terms: statins, HMG-CoA inhibitors, Clostridium difficile, Clostridium difficile associated diarrhea, and Clostridium difficile infection. Additional references were identified from a review of literature citations. Studies evaluating statin effects on C difficile-related outcomes were included.
Results
A total of 8 studies were identified for inclusion in this review. All studies were retrospective. Five studies reported the association between statin use and the development of CDI, suggesting that statins may decrease risk of CDI development in patients already on statin. In one study, there was an improved treatment response against CDI with the use of statin. Three retrospective studies evaluated statin use and mortality from CDI and only one study found significant mortality benefit in statin users.
Conclusions
Statin use may have a protective effect against the development of CDI and improve CDI treatment success; however, it is unclear if use confers a mortality benefit. Current data remain sparse and larger, prospective studies are needed to confirm current results and identify the specific population that may benefit the most from this intervention.
ZhangSPalazuelos-MunozS, et al.Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447.
3.
LessaFCMuYBambergWM, et al.Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834.
4.
KwonJHOlsenMADubberkeER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):123–134.
5.
JangiSLamontJT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010;51(1):2–7.
6.
O’ConnorJRJohnsonSGerdingDN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009;136(6):1913–1924.
7.
ChenSSunCWangH, et al.The role of rho GTPases in toxicity of Clostridium difficile toxins. Toxins (Basel). 2015;7(12):5254–5267.
8.
SubausteMCVon HerrathMBenardV, et al.Rho family proteins modulate rapid apoptosis induced by cytotoxic T lymphocytes and Fas. J Biol Chem. 2000;275(13):9725–9733.
9.
JankTGiesemannTAktoriesK. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology. 2007;17(4):15R–22R.
10.
CohenSHGerdingDNJohnsonS, et al.Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455.
11.
McDonaldLCOwingsMJerniganDB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12(3):409–415.
12.
ShorrAFZilberbergMDWangL, et al.Mortality and costs in Clostridium difficile infection among the elderly in the United States. Infect Control Hosp Epidemiol. 2016;37(11):1331–1336.
13.
JohnsonSSamoreMHFarrowKA, et al.Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341(22):1645–1651.
14.
PriviteraGScarpelliniPOrtisiG, et al.Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35(1):208–210.
15.
YeeJDixonCMMcLeanAP, et al.Clostridium difficile disease in a department of surgery: the significance of prophylactic antibiotics. Arch Surg. 1991;126(2):241–246.
16.
AnandAGlattAE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109–113.
17.
DialSDelaneyJABarkunAN, et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile–associated disease. JAMA. 2005;294(23):2989–2995.
18.
CunninghamRDaleBUndyB, et al.Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–245.
19.
DialSAlrasadiKManoukianC, et al.Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171(1):33–38.
FriedmanG. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41(4):763–779.
23.
TurnerRBSmithCBMartelloJL, et al.Role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother. 2014;48(6):772–776.
24.
SalamiJAWarraichHValero-ElizonodoJ, et al.National trends in statin use and expenditures in the us adult population from 2002 to 2013. JAMA Cardiol. 2017;2(1):56–65.
25.
JainMKRidkerPM. Anti-inflammatory of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987.
26.
WilliamsJKSukhovaGKHerringtonDM, et al.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31(3):684–691.
27.
WolfrumSJensenKSLiaoJK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23(5):729–736.
28.
DobeshPPKlepserDGMcGuireTR, et al.Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy. 2009;29(6):621–630.
29.
RothbergMBBigelowCPekowPS, et al.Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med. 2012;27(3):280–286.
30.
CaffeyARTimbrookTTNohE, et al.Evidence to support continuation of statin therapy in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;61(3):e02228–16.
31.
LiaoJKLaufsU. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
32.
NaggieSMillerBAZuzakKB, et al.A case-control study of community-associated Clostridium difficile Infection: no role for proton pump inhibitors. Am J Med. 2011;124(3):276.e1–e7.
33.
Motzkus-FeagansCAPakyzAPolkR, et al.Statin use and the risk of Clostridium difficile in academic medical centres. Gut. 2012;61(11):1538–1542.
34.
NseirWBisharaJMograbiJ, et al.Do statins protect against the development of Clostridium difficile-associated diarrhea?J Antimicrob Chemother. 2013;68(6):1889–1893.
35.
TartofSYRiegGKWeiR, et al.Comprehensive assessment across the healthcare continuum: risk of hospital-associated Clostridium difficile infection due to outpatient and inpatient antibiotic exposure. Infect Control Hosp Epidemiol. 2015;36(12):1409–1416.
36.
CarvourMLWilderSLRyanK, et al.Predictors of Clostridium difficile infection and predictive impact of probiotic use in a diverse hospital-wide cohort. Am J Infect Control. 2019;47(1):2–8.
37.
ParkSWChoiARLeeHJ, et al.The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther. 2013;38(6):619–627.
38.
SalibaWBarnett-GrinessOEliasM, et al.Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect. 2014;20(10):1061–1066.
39.
AtamnaAYahavDEliakim-RazN, et al.The effect of statins on the outcome of Clostridium difficile infection in hospitalized patients. Eur J Clin Microbiol Infect Dis. 2016;35(5):779–784.
40.
AndoHTakamuraTOtaT, et al.Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000;294(3):1043–1046.
RikitakeYLiaoJK. Rho GTPases, statins, and nitric oxide. Circ Res. 2005;97(12):1232–1235.
43.
CaiAZhouYLiL. Rho-GTPase and atherosclerosis: pleiotropic effects of statins. J Am Heart Assoc. 2015;4(7):e002113. doi:10.1161/JAHA.115.002113
44.
MaherBMDhonnchuTNBurkeJP, et al.Statins alter neutrophil migration by modulating cellular Rho activity—a potential mechanism for statins-mediated pleotropic effects?. J Leukoc Biol. 2009;85:186–193. doi:10.1189/jlb.0608382
45.
IwataAShiraiRIshiiH, et al.Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol. 2012;168(2):234–240.
46.
McGuireTDobeshPKlepserD, et al.Clinically important interaction between statin drugs and Clostridium difficile toxin?Med Hypotheses. 2009;73(6):1045–1057.
SurawiczCMBrandtLJBinionMD, et al.Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013:108(4):478–498.
49.
LongtinYTrottierSBrochuG, et al.Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis. 2013;56(1):67–73.
50.
CrobachMJPlancheTEckertC, et al.European society of clinical microbiology and infectious diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(suppl 4):S63–S81.
51.
TariqRMukhijaDGuptaA, et al.Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis. Infect Drug Resist. 2018;11:405–416.
52.
StoneNJRobinsonJGLichtensteinAH, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 pt B):2889–2934.
